POTS (Postural Orthostatic Tachycardia Syndrome): What the Non-Drug Evidence Actually Shows

Medical disclaimer: This article is for educational and informational purposes only, intended for healthcare practitioners and informed readers seeking to understand the current evidence base for postural orthostatic tachycardia syndrome. Nothing here constitutes medical advice, diagnosis, or a personalised treatment plan. POTS requires formal diagnosis by a qualified medical practitioner, typically involving orthostatic vital sign testing or tilt-table assessment. If you experience tachycardia, dizziness, or near-syncope on standing, seek professional evaluation before pursuing any self-directed protocol.

What Is POTS?

Postural orthostatic tachycardia syndrome (POTS) is a form of chronic orthostatic intolerance defined by an excessive heart rate response to standing without the blood pressure drop that characterises orthostatic hypotension. The consensus diagnostic criteria, set out in the 2019 Canadian Cardiovascular Society position statement and reaffirmed in more recent reviews, require a sustained heart rate increase of at least 30 beats per minute within 10 minutes of standing or head-up tilt in adults (at least 40 beats per minute in adolescents aged 12 to 19), in the absence of a sustained blood pressure fall of more than 20/10 mmHg, accompanied by orthostatic symptoms for six months or longer that are relieved by lying down, with other causes of sinus tachycardia excluded.

A 2026 state-of-the-art review published in Heart, Lung and Circulation by Lau and colleagues describes POTS as a heterogeneous disorder of the autonomic nervous system with a broad symptom burden that frequently causes significant diagnostic delay, and the authors call for expanded multidisciplinary services to meet a growing patient population. That same review is a useful entry point for practitioners because it frames POTS explicitly as a condition requiring both non-pharmacological and pharmacological management tailored to the individual, rather than a single standard protocol.

POTS commonly overlaps with hypermobile Ehlers-Danlos syndrome, mast cell activation, and post-viral illness, including long COVID. For a detailed treatment of the mast cell and connective-tissue overlap, see our MCAS naturopathic guide, which covers the POTS-MCAS-hEDS cluster in depth.

Proposed Mechanisms

POTS is not a single disease but a haemodynamic pattern with several contributing pathophysiologies, which likely explains why no single treatment works for every patient.

Hypovolaemic POTS involves reduced circulating blood volume, so venous return falls sharply on standing and the heart compensates with tachycardia. This subtype responds most predictably to volume-expanding interventions such as sodium and fluid loading.

Neuropathic POTS involves a partial, length-dependent autonomic neuropathy affecting the lower limbs, reducing venous vasoconstriction on standing and causing blood pooling. This subtype is frequently seen alongside small-fibre neuropathy and diabetic or post-viral autonomic injury.

Hyperadrenergic POTS involves excessive sympathetic nervous system activation, with some patients showing elevated standing plasma norepinephrine and prominent tremor, anxiety, and hypertension on standing rather than hypotension.

Autoimmune-associated POTS involves autoantibodies against adrenergic and muscarinic acetylcholine receptors, identified in a subset of patients, with functional effects on receptor signalling that plausibly contribute to autonomic dysregulation. This mechanism overlaps with findings described in ME/CFS and long COVID cohorts.

Most patients show features of more than one subtype, and the subtypes are not mutually exclusive within an individual.

The Trial Evidence: What a 2025 Systematic Review Found

A systematic review by Kwok and colleagues, published in Trends in Cardiovascular Medicine in November 2025, identified 21 randomized controlled trials enrolling 750 patients between 2000 and 2023, the largest such synthesis to date for POTS treatments. The review assessed both pharmacological interventions (propranolol, midodrine, pyridostigmine, ivabradine, desmopressin, melatonin, atomoxetine, modafinil, sertraline, and intravenous immunoglobulin) and non-pharmacological approaches (increased dietary sodium, exercise training, compression garments, and assistive devices).

The authors' overall conclusion is an important calibration point: many small trials exist, but the evidence base remains too fragmented to establish any single treatment, drug or non-drug, as a confirmed first-line therapy. That honest limitation should temper how confidently any POTS intervention, including the naturopathic ones below, is presented to patients.

Within that limited evidence base, three non-pharmacological interventions have the most direct randomized or controlled support.

Exercise Reconditioning

The foundational trial, conducted by Fu, Levine, and colleagues and published in Hypertension in 2011, randomised 19 POTS patients through a four-week double-blind propranolol-versus-placebo phase followed by three months of structured exercise training, with 15 healthy controls for comparison. Exercise training increased blood volume and left ventricular mass, produced no significant change in cardiac output, and modestly increased the aldosterone-to-renin ratio, consistent with improved renal-adrenal responsiveness. On the SF-36 quality of life measure, physical functioning scores rose from a mean of 33 to 50 and social functioning from 37 to 48 (both statistically significant), while propranolol alone produced no significant quality of life change. The authors concluded that exercise training, not beta-blockade, was the intervention that restored upright haemodynamics.

The training protocol that emerged from this and follow-up work at UT Southwestern, sometimes called the Levine protocol, begins with recumbent or semi-recumbent aerobic exercise (rowing machine, recumbent bike, or swimming) to avoid provoking orthostatic symptoms, then progresses gradually toward upright exercise over several months as tolerance improves. A 2016 registry study applying this approach outside the original research laboratory reported that 71% of 103 patients who completed the multi-month program no longer met the 30 bpm heart rate criterion on standing, with mean orthostatic heart rate increase falling from 46 to 23 bpm. Registry data of this kind is weaker evidence than a randomized trial, since patients who complete a demanding months-long program are a self-selected group, but the consistency with the smaller RCT strengthens the overall picture.

Exercise reconditioning is not appropriate for every POTS patient. Where POTS overlaps with ME/CFS and post-exertional malaise is present, graded exercise carries real risk of harm and pacing takes priority over reconditioning; our ME/CFS clinical protocol guide sets out why that caution is non-negotiable in that overlap population. Screening for post-exertional malaise before recommending any exercise program is an essential first step in POTS patients with fatigue-predominant presentations.

Compression Garments

Bourne and colleagues, in a randomized crossover trial of 30 POTS patients published in the Journal of the American College of Cardiology in 2021, tested four compression conditions during head-up tilt: no compression, lower-leg only, abdominal and thigh, and full abdominal-and-leg compression. Standing heart rate fell in a dose-dependent manner with compression coverage: 109 bpm with no compression, 103 bpm with leg-only, 97 bpm with abdominal and thigh, and 92 bpm with full compression, with symptom scores improving correspondingly. The effect was attributed to improved stroke volume from reduced venous pooling in the abdomen and lower body, and abdominal compression appeared to contribute more than leg compression alone. A subsequent community-based trial using commercially available compression tights confirmed that the acute heart rate and symptom benefits persisted for several hours of continuous wear, including in patients already taking heart rate-lowering medication.

Sodium and Fluid Loading

Sodium and fluid supplementation is close to universally recommended in POTS clinical guidance, but the systematic review evidence for it specifically is thinner than for exercise or compression. A randomized trial by Medow and colleagues, published in the Journal of Pediatrics in 2019, compared intravenous saline, oral rehydration solution, and no treatment in 10 children with POTS and 15 controls under lower-body negative pressure stress. Both saline and oral rehydration solution significantly improved orthostatic tolerance in the POTS group, with oral rehydration solution also significantly raising cerebral blood flow velocity, while healthy controls showed no benefit from either intervention. This supports acute volume loading as an effective short-term strategy, particularly before activities known to provoke symptoms.

What the evidence does not yet establish is the optimal long-term sodium target, and whether the benefit of high-salt diets comes from the sodium itself or from the accompanying fluid intake. This is a genuine gap: sodium loading is standard advice in POTS management despite this thinner trial base, which is exactly the kind of honesty this evidence review aims for rather than overstating certainty. Typical clinical guidance suggests 3 to 10 grams of additional sodium daily alongside 2 to 3 litres of fluid, introduced gradually and only under medical supervision given the contraindication in uncontrolled hypertension or renal disease.

A Naturopathic Assessment Framework

Naturopathic assessment of suspected POTS should not replace formal cardiology or autonomic specialist evaluation, but it adds useful structure to the initial workup and ongoing monitoring.

Baseline orthostatic testing: A 10-minute stand test, heart rate and blood pressure recorded supine and at 2, 5, and 10 minutes standing, is a reasonable office-based screen, though formal tilt-table testing remains the diagnostic reference standard where available.

Exclusion of secondary causes: Iron studies (ferritin, transferrin saturation), thyroid panel, and a basic metabolic panel should be reviewed before attributing symptoms to primary POTS, since anaemia and thyroid dysfunction both produce orthostatic tachycardia independently.

Screening for overlap conditions: Given the well-documented POTS-MCAS-hEDS cluster and the high prevalence of POTS in ME/CFS and long COVID cohorts, a structured symptom history covering hypermobility (Beighton score), mast cell mediator symptoms, and post-exertional malaise should be routine rather than incidental.

Hydration and sodium diary: Before recommending supplementation, a brief diary of current fluid and dietary sodium intake identifies patients who are already close to typical clinical targets versus those with meaningful room for adjustment.

Graded activity planning: Where post-exertional malaise is absent, a structured, recumbent-first exercise plan modelled on the published reconditioning protocols is reasonable to introduce gradually and in coordination with the patient's treating physician. Where post-exertional malaise is present, pacing takes priority and exercise progression should not be pushed against symptoms.

What the Evidence Does and Doesn't Support

Exercise reconditioning has the strongest direct trial support among non-drug POTS interventions, with a randomized comparison against a standard pharmacological agent and reasonably consistent registry follow-up. Compression garments have solid acute physiological trial evidence for symptom and heart rate reduction, with real-world confirmation that the benefit persists over several hours. Sodium and fluid loading has genuine supportive evidence for acute symptom relief, but the long-term dosing evidence is weaker than the strength of the standard clinical recommendation would suggest, and no large sodium-specific randomized trial in adults has yet been completed.

What the evidence does not establish is a single first-line non-drug protocol suitable for all POTS subtypes, meaningful head-to-head comparisons between the non-pharmacological approaches, or long-term outcome data beyond a few months for most interventions. The 2025 systematic review's own conclusion, that current trials remain too small and heterogeneous to settle first-line treatment questions, applies to naturopathic and conventional interventions alike. Patients and practitioners should treat POTS management as an individualised, iterative process guided by subtype and overlap conditions, not a fixed protocol applied uniformly.

Clinical Summary

POTS is diagnosed by a sustained heart rate increase of at least 30 bpm (40 bpm in adolescents) within 10 minutes of standing, without significant orthostatic hypotension, and with symptoms present for six months or longer. The 2025 systematic review of 21 randomized trials in 750 patients found real but still-limited evidence across pharmacological and non-pharmacological treatments. Among non-drug approaches, structured exercise reconditioning has the strongest randomized evidence, waist-high compression garments have solid acute physiological trial support, and sodium and fluid loading has good evidence for acute symptom relief despite thinner long-term data than its widespread use would suggest. Screening for the POTS-MCAS-hEDS cluster and for post-exertional malaise before recommending exercise are the two most clinically important steps in a naturopathic assessment.

Key references: Kwok CS, Lee S, Hall M, Qureshi AI, Lip GYH, Loke YK, Raj SR, Holroyd E. The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials. Trends Cardiovasc Med. 2025;35(8):517-527. doi:10.1016/j.tcm.2025.07.001. Lau DH, Fedorowski A, Raj SR, et al. Postural Orthostatic Tachycardia Syndrome: A State-of-the-Art Review. Heart Lung Circ. 2026;35(2):171-185. doi:10.1016/j.hlc.2025.09.004. Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011;58(2):167-175. doi:10.1161/HYPERTENSIONAHA.111.172262. Bourne KM, Sheldon RS, Hall J, et al. Compression Garment Reduces Orthostatic Tachycardia and Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77(3):285-296. doi:10.1016/j.jacc.2020.11.040. Medow MS, Guber K, Chokshi S, Terilli C, Visintainer P, Stewart JM. The Benefits of Oral Rehydration on Orthostatic Intolerance in Children with Postural Tachycardia Syndrome. J Pediatr. 2019;214:96-102. doi:10.1016/j.jpeds.2019.07.041.